Filed
pursuant to Rule 424(b)(3)
Registration
No. 333-291832
Prospectus
Supplement No. 6
(To
Prospectus dated December 11, 2025)
Jupiter
Neurosciences, Inc.
This
prospectus supplement updates, amends and supplements the prospectus dated December 11, 2025 (the “Prospectus”), which forms
a part of our Registration Statement on Form S-1 (Registration No. 333-291832) and is being filed to
update, amend and supplement the information included in the Prospectus with information contained in our Current Report on Form 8-K,
which was filed with the Securities and Exchange Commission (the “SEC”) on June 22, 2026 (the “Current Report”).
Accordingly, we have attached the Current Report to this prospectus supplement. Capitalized terms used in this prospectus supplement
and not otherwise defined herein have the meanings specified in the Prospectus.
This
prospectus supplement is not complete without the Prospectus. This prospectus supplement should be read in conjunction with the Prospectus,
which is to be delivered with this prospectus supplement, and is qualified by reference thereto, except to the extent that the information
in this prospectus supplement updates or supersedes the information contained in the Prospectus. Please keep this prospectus supplement
with your Prospectus for future reference.
Shares
of our common stock, par value $0.0001 per share (our “Common Stock”), are listed on The Nasdaq Stock Market, LLC under the
symbol “JUNS.” On June 18, 2026, the closing price of our Common Stock was $0.2380 per share.
Investing
in our securities involves risks that are described in the “Risk Factors” section
of the Prospectus.
Neither
the SEC nor any state securities commission has approved or disapproved of the securities to be issued under the Prospectus or this prospectus
supplement or determined if the Prospectus or this prospectus supplement is truthful or complete. Any representation to the contrary
is a criminal offense.
The
date of this prospectus supplement is June 22, 2026.
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
June
17, 2026
Date
of Report (Date of earliest event reported)
JUPITER
NEUROSCIENCES, INC.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
001-41265 |
|
47-4828381 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
| 1001
North US HWY 1, Suite 504, Jupiter, FL |
|
33477 |
| (Address
of principal executive offices) |
|
(Zip
Code) |
(561)
406-6154
Registrant’s
telephone number, including area code
Check
the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of
the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock |
|
JUNS |
|
Nasdaq
Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
Growth Company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
On
June 17, 2026, Allison W. Brady, a member of the Board of Directors (the “Board”) of Jupiter Neurosciences, Inc. (the “Company”),
informed the Company of her decision to resign from the Board, effective immediately. Ms. Brady also resigned from her positions as a
member of the Audit Committee and the Compensation Committee of the Board, effective as of the same date. Her decision to resign is not
the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Ms.
Brady’s seat on the Board will remain vacant until the Company’s annual meeting on July 22, 2026.
Item
9.01. Financial Statements and Exhibits.
| Exhibit
No. |
|
Description |
| |
|
|
| 104 |
|
Cover
Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
JUPITER
NEUROSCIENCES, INC. |
| |
|
|
| Date:
June 22, 2026 |
By: |
/s/
Christer Rosén |
| |
Name:
|
Christer
Rosén |
| |
Title:
|
Chief
Executive Officer |
